Tags

Type your tag names separated by a space and hit enter

[Primary combined oral antidiabetic therapy in type-2 diabetes mellitus].
Orv Hetil. 2002 Oct 27; 143(43):2441-7.OH

Abstract

New target values of the metabolic control and recent directions in the therapeutic strategies of type 2 diabetes mellitus are overviewed. Attention is called to the atherogenic effect of blood glucose elevations exceeding physiological level, even when only post-prandial and with short duration. The significance of early phase prandial insulin secretion in the metabolic state is underlined, and the related new therapeutic possibilities are discussed. Practical guidelines are given to the introduction of oral antidiabetic therapy, and the importance of the early, aggressive, combined treatment with a complex mechanism of action is emphasized.

Authors+Show Affiliations

Winkler G
II. Belgyógyászati Osztály, Fóvárosi Szent János Kórház, Budapest.
Baranyi E
No affiliation info available

MeSH

Administration, OralBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationHumansHyperglycemiaHypoglycemic AgentsInsulinPostprandial PeriodRisk Factors

Pub Type(s)

English Abstract
Journal Article
Review

Language

hun

PubMed ID

12455146

Citation

Winkler, Gábor, and Eva Baranyi. "[Primary Combined Oral Antidiabetic Therapy in Type-2 Diabetes Mellitus]." Orvosi Hetilap, vol. 143, no. 43, 2002, pp. 2441-7.
Winkler G, Baranyi E. [Primary combined oral antidiabetic therapy in type-2 diabetes mellitus]. Orv Hetil. 2002;143(43):2441-7.
Winkler, G., & Baranyi, E. (2002). [Primary combined oral antidiabetic therapy in type-2 diabetes mellitus]. Orvosi Hetilap, 143(43), 2441-7.
Winkler G, Baranyi E. [Primary Combined Oral Antidiabetic Therapy in Type-2 Diabetes Mellitus]. Orv Hetil. 2002 Oct 27;143(43):2441-7. PubMed PMID: 12455146.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Primary combined oral antidiabetic therapy in type-2 diabetes mellitus]. AU - Winkler,Gábor, AU - Baranyi,Eva, PY - 2002/11/29/pubmed PY - 2003/1/11/medline PY - 2002/11/29/entrez SP - 2441 EP - 7 JF - Orvosi hetilap JO - Orv Hetil VL - 143 IS - 43 N2 - New target values of the metabolic control and recent directions in the therapeutic strategies of type 2 diabetes mellitus are overviewed. Attention is called to the atherogenic effect of blood glucose elevations exceeding physiological level, even when only post-prandial and with short duration. The significance of early phase prandial insulin secretion in the metabolic state is underlined, and the related new therapeutic possibilities are discussed. Practical guidelines are given to the introduction of oral antidiabetic therapy, and the importance of the early, aggressive, combined treatment with a complex mechanism of action is emphasized. SN - 0030-6002 UR - https://www.unboundmedicine.com/medline/citation/12455146/[Primary_combined_oral_antidiabetic_therapy_in_type_2_diabetes_mellitus]_ DB - PRIME DP - Unbound Medicine ER -